Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection

Francesco Di Mario, Ali Mahamat Moussa, Lucas Giovanni Cavallaro, Pietro Caruana, Roberta Merli, Simone Bertolini, Veronica Iori, Giulia Martina Cavestro, Nadia Dal Bò, Alberto Pilotto, Angelo Franzé, Gioacchino Leandro

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection. Aim: To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII levels were determined in 156 H. pylori-positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity. Results: H. pylori-positive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 ± 7.4 vs. 8.6 ± 3.7 μg/l; p <0.001). The best sPGII cut-off for predicting H. pylori infection was 9.93 μg/l (sensitivity 83%, specificity 73%). The best cut-off values to evaluate success of therapy were: sPGII of 9.47 μg/l, a sPGII variation level (difference between baseline and after therapy) of 4.54 μg/l, and a sPGII Δvalue (sPGII variation divided by sPGII before therapy) of 25% (sensitivity 93%, specificity 91%). Conclusions: sPGII levels may be used as a reliable marker of H. pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.

Original languageEnglish
Pages (from-to)167-172
Number of pages6
JournalDigestion
Volume70
Issue number3
DOIs
Publication statusPublished - 2004

Fingerprint

Pepsinogen C
Helicobacter Infections
Helicobacter pylori
Serum
Stomach
Therapeutics
Sensitivity and Specificity
Gastroscopy

Keywords

  • H. pylori, eradication therapy
  • Helicobacter pylori
  • Serum pepsinogen II

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Di Mario, F., Moussa, A. M., Cavallaro, L. G., Caruana, P., Merli, R., Bertolini, S., ... Leandro, G. (2004). Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection. Digestion, 70(3), 167-172. https://doi.org/10.1159/000081517

Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection. / Di Mario, Francesco; Moussa, Ali Mahamat; Cavallaro, Lucas Giovanni; Caruana, Pietro; Merli, Roberta; Bertolini, Simone; Iori, Veronica; Cavestro, Giulia Martina; Dal Bò, Nadia; Pilotto, Alberto; Franzé, Angelo; Leandro, Gioacchino.

In: Digestion, Vol. 70, No. 3, 2004, p. 167-172.

Research output: Contribution to journalArticle

Di Mario, F, Moussa, AM, Cavallaro, LG, Caruana, P, Merli, R, Bertolini, S, Iori, V, Cavestro, GM, Dal Bò, N, Pilotto, A, Franzé, A & Leandro, G 2004, 'Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection', Digestion, vol. 70, no. 3, pp. 167-172. https://doi.org/10.1159/000081517
Di Mario F, Moussa AM, Cavallaro LG, Caruana P, Merli R, Bertolini S et al. Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection. Digestion. 2004;70(3):167-172. https://doi.org/10.1159/000081517
Di Mario, Francesco ; Moussa, Ali Mahamat ; Cavallaro, Lucas Giovanni ; Caruana, Pietro ; Merli, Roberta ; Bertolini, Simone ; Iori, Veronica ; Cavestro, Giulia Martina ; Dal Bò, Nadia ; Pilotto, Alberto ; Franzé, Angelo ; Leandro, Gioacchino. / Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection. In: Digestion. 2004 ; Vol. 70, No. 3. pp. 167-172.
@article{1a2bf2ac37af425bae58eea25d701235,
title = "Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection",
abstract = "Background: Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection. Aim: To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII levels were determined in 156 H. pylori-positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity. Results: H. pylori-positive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 ± 7.4 vs. 8.6 ± 3.7 μg/l; p <0.001). The best sPGII cut-off for predicting H. pylori infection was 9.93 μg/l (sensitivity 83{\%}, specificity 73{\%}). The best cut-off values to evaluate success of therapy were: sPGII of 9.47 μg/l, a sPGII variation level (difference between baseline and after therapy) of 4.54 μg/l, and a sPGII Δvalue (sPGII variation divided by sPGII before therapy) of 25{\%} (sensitivity 93{\%}, specificity 91{\%}). Conclusions: sPGII levels may be used as a reliable marker of H. pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.",
keywords = "H. pylori, eradication therapy, Helicobacter pylori, Serum pepsinogen II",
author = "{Di Mario}, Francesco and Moussa, {Ali Mahamat} and Cavallaro, {Lucas Giovanni} and Pietro Caruana and Roberta Merli and Simone Bertolini and Veronica Iori and Cavestro, {Giulia Martina} and {Dal B{\`o}}, Nadia and Alberto Pilotto and Angelo Franz{\'e} and Gioacchino Leandro",
year = "2004",
doi = "10.1159/000081517",
language = "English",
volume = "70",
pages = "167--172",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection

AU - Di Mario, Francesco

AU - Moussa, Ali Mahamat

AU - Cavallaro, Lucas Giovanni

AU - Caruana, Pietro

AU - Merli, Roberta

AU - Bertolini, Simone

AU - Iori, Veronica

AU - Cavestro, Giulia Martina

AU - Dal Bò, Nadia

AU - Pilotto, Alberto

AU - Franzé, Angelo

AU - Leandro, Gioacchino

PY - 2004

Y1 - 2004

N2 - Background: Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection. Aim: To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII levels were determined in 156 H. pylori-positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity. Results: H. pylori-positive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 ± 7.4 vs. 8.6 ± 3.7 μg/l; p <0.001). The best sPGII cut-off for predicting H. pylori infection was 9.93 μg/l (sensitivity 83%, specificity 73%). The best cut-off values to evaluate success of therapy were: sPGII of 9.47 μg/l, a sPGII variation level (difference between baseline and after therapy) of 4.54 μg/l, and a sPGII Δvalue (sPGII variation divided by sPGII before therapy) of 25% (sensitivity 93%, specificity 91%). Conclusions: sPGII levels may be used as a reliable marker of H. pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.

AB - Background: Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection. Aim: To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII levels were determined in 156 H. pylori-positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity. Results: H. pylori-positive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 ± 7.4 vs. 8.6 ± 3.7 μg/l; p <0.001). The best sPGII cut-off for predicting H. pylori infection was 9.93 μg/l (sensitivity 83%, specificity 73%). The best cut-off values to evaluate success of therapy were: sPGII of 9.47 μg/l, a sPGII variation level (difference between baseline and after therapy) of 4.54 μg/l, and a sPGII Δvalue (sPGII variation divided by sPGII before therapy) of 25% (sensitivity 93%, specificity 91%). Conclusions: sPGII levels may be used as a reliable marker of H. pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.

KW - H. pylori, eradication therapy

KW - Helicobacter pylori

KW - Serum pepsinogen II

UR - http://www.scopus.com/inward/record.url?scp=19944431611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944431611&partnerID=8YFLogxK

U2 - 10.1159/000081517

DO - 10.1159/000081517

M3 - Article

VL - 70

SP - 167

EP - 172

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 3

ER -